IL260193A - Tlr inhibitory oligonucleotides and their use - Google Patents
Tlr inhibitory oligonucleotides and their useInfo
- Publication number
- IL260193A IL260193A IL260193A IL26019318A IL260193A IL 260193 A IL260193 A IL 260193A IL 260193 A IL260193 A IL 260193A IL 26019318 A IL26019318 A IL 26019318A IL 260193 A IL260193 A IL 260193A
- Authority
- IL
- Israel
- Prior art keywords
- inhibitory oligonucleotides
- tlr inhibitory
- tlr
- oligonucleotides
- inhibitory
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015255008 | 2015-12-25 | ||
| PCT/JP2016/088418 WO2017111045A1 (en) | 2015-12-25 | 2016-12-22 | Tlr inhibitory oligonucleotides and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL260193A true IL260193A (en) | 2018-07-31 |
Family
ID=59090457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL260193A IL260193A (en) | 2015-12-25 | 2018-06-21 | Tlr inhibitory oligonucleotides and their use |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10806749B2 (enExample) |
| EP (1) | EP3394263B1 (enExample) |
| JP (1) | JP7079495B2 (enExample) |
| KR (1) | KR20180089531A (enExample) |
| CN (1) | CN108431228A (enExample) |
| AU (1) | AU2016375543A1 (enExample) |
| CA (1) | CA3009154A1 (enExample) |
| IL (1) | IL260193A (enExample) |
| WO (1) | WO2017111045A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3468605A4 (en) | 2016-06-08 | 2020-01-08 | President and Fellows of Harvard College | MANIPULATED VIRAL VECTOR TO REDUCE INDUCTION OF IGNITION AND IMMUNE REACTIONS |
| US10350307B2 (en) * | 2017-09-18 | 2019-07-16 | General Electric Company | In vivo RNA or protein expression using double-stranded concatemeric DNA including phosphorothioated nucleotides |
| AU2018364542A1 (en) | 2017-11-08 | 2020-04-16 | President And Fellows Of Harvard College | Compositions and methods for inhibiting viral vector-induced inflammatory responses |
| CN109266732A (zh) * | 2018-09-13 | 2019-01-25 | 中山大学附属第医院 | TLR7和TLR8作为IgA肾病预防治疗靶点的应用及TLR7的抑制剂及其应用 |
| CN114569722B (zh) * | 2022-03-07 | 2022-11-22 | 广州市妇女儿童医疗中心 | 抑制血小板焦亡的试剂在制备预防和/或治疗脓毒症的药物中的用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5011520A (enExample) | 1973-05-31 | 1975-02-06 | ||
| AU2003275776B2 (en) * | 2002-11-08 | 2009-06-18 | Jingang Medicine (Australia) Pty Ltd | A method for optimising gene expression using synonymous codon optimisation |
| IL161579A0 (en) * | 2004-04-22 | 2004-09-27 | Mor Research Applic Ltd | ANTISENSE OLIGONUCLEOTIDES AGAINST cPLA2, COMPOSITIONS AND USES THEREOF |
| ATE541928T1 (de) * | 2005-03-31 | 2012-02-15 | Calando Pharmaceuticals Inc | Inhibitoren der untereinheit 2 der ribonukleotidreduktase und ihre verwendungen |
| JP5011520B2 (ja) | 2005-08-12 | 2012-08-29 | 国立大学法人 長崎大学 | 新規ヒト形質細胞様樹状細胞株 |
| US8030289B2 (en) | 2008-08-06 | 2011-10-04 | Changchun Huapu Biotechnology Co., Ltd. | Oligonucleotide and use thereof |
| PL2154144T3 (pl) | 2008-08-06 | 2015-04-30 | Changchun Huapu Biotechnology Co Ltd | Oligonukleotydy i ich zastosowanie |
| CN101696434A (zh) * | 2009-10-27 | 2010-04-21 | 中国科学院过程工程研究所 | β-聚苹果酸发酵新工艺 |
| WO2014082254A1 (en) * | 2012-11-29 | 2014-06-05 | Changchun Huapu Biotechnology Co., Ltd | Inhibitory oligonucleotide and use thereof |
| US20170240896A1 (en) * | 2014-02-07 | 2017-08-24 | Sbi Biotech, Co., Ltd. | Inhibitory Oligonucleotides for Treating Tumors |
-
2016
- 2016-12-22 CN CN201680076044.XA patent/CN108431228A/zh active Pending
- 2016-12-22 KR KR1020187021100A patent/KR20180089531A/ko not_active Withdrawn
- 2016-12-22 WO PCT/JP2016/088418 patent/WO2017111045A1/en not_active Ceased
- 2016-12-22 AU AU2016375543A patent/AU2016375543A1/en not_active Abandoned
- 2016-12-22 US US16/064,926 patent/US10806749B2/en active Active
- 2016-12-22 EP EP16878931.1A patent/EP3394263B1/en active Active
- 2016-12-22 JP JP2018533265A patent/JP7079495B2/ja active Active
- 2016-12-22 CA CA3009154A patent/CA3009154A1/en not_active Abandoned
-
2018
- 2018-06-21 IL IL260193A patent/IL260193A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180089531A (ko) | 2018-08-08 |
| JP2019500873A (ja) | 2019-01-17 |
| AU2016375543A1 (en) | 2018-06-28 |
| CA3009154A1 (en) | 2017-06-29 |
| EP3394263A1 (en) | 2018-10-31 |
| EP3394263A4 (en) | 2019-08-21 |
| CN108431228A (zh) | 2018-08-21 |
| JP7079495B2 (ja) | 2022-06-02 |
| US20190008888A1 (en) | 2019-01-10 |
| US10806749B2 (en) | 2020-10-20 |
| EP3394263B1 (en) | 2025-02-26 |
| WO2017111045A1 (en) | 2017-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL261832B (en) | Oligonucleotide probes and uses thereof | |
| IL280863A (en) | Autotaxin inhibitors and uses thereof | |
| EP3314027A4 (en) | THERAPEUTIC OLIGONUCLEOTIDES | |
| EP3664817A4 (en) | CHEMICALLY MODIFIED OLIGONUCLEOTIDES | |
| EP3408391A4 (en) | BRANCHED OLIGONUCLEOTIDES | |
| IL250587B (en) | Neutralization of inhibitory pathways in lymphocytes | |
| EP3328873A4 (en) | TARGETED OLIGONUCLEOTIDES | |
| DK3197883T3 (da) | Hidtil ukendte forbindelser | |
| DK3152607T3 (da) | En antiresonant hulkernefiber | |
| BR112017018413A2 (pt) | tratamento de pancreatite | |
| BR112017010262A2 (pt) | combinações de inibidor de tlr e inibidor de turosina-quinas de bruton | |
| EP3285660A4 (en) | TOURNIQUET | |
| EP3468421A4 (en) | CUTLERY DISPENSER | |
| KR20180084630A (ko) | 항균 매트 | |
| FI20155008A7 (fi) | Ajoneuvoavusteinen työlaite | |
| EP3409779A4 (en) | Single-stranded oligonucleotide | |
| DK3478843T3 (da) | Oligonukleotider omfattende modificerede nukleosider | |
| DK3321279T3 (da) | Exenatidmodificeringsmiddel og anvendelse deraf | |
| PT3337506T (pt) | Combinações e suas utilizações | |
| EP3619311C0 (en) | DNA ASSEMBLY | |
| FR3045729B1 (fr) | Biomotors gdi | |
| EP3394263A4 (en) | OLIGONUCLEOTIDES INHIBITORS OF TLR AND THEIR USE | |
| DK3329004T3 (da) | Terapeutiske oligonukleotider | |
| DE112016002351A5 (de) | Halteelement | |
| BR112017018932A2 (pt) | etv2 e usos do mesmo |